14. (ABUS)-How Will Patent Win Impact Stock Outlook?
습관중독
Dec. 17, 2021, JR Research Summary In December 2021, ABUS reported its victory in the patent dispute over Moderna, involving its licensed four-lipid nanoparticles delivery system. The future royalties from mRNA COVID-19 vaccine producers remain uncertain as the US government pushes for vaccine IP waivers. ABUS' Revenue Stream From Patent Licencing As a clinical-stage biopharmaceutical company, A..